 "Alembic Pharma subsidiary Orit Lab gets US FDA nod for peptic ulcer drug")
Drug firm Alembic Pharmaceuticals Tuesday said its subsidiary has received the US health regulator's nod for Glycopyrrolate tablets, used in the treatment of peptic ulcer.
The company's wholly owned subsidiary Orit Laboratories LLC has received approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Glycopyrrolate tablets USP in the strengths of 1 mg and 2mg, Alembic Pharmaceuticals said in a BSE filing.
The product is a therapeutic equivalent of Casper Pharma's Robinul and Robinul Forte tablets, it added.
Quoting IQVIA data, Alembic Pharmaceuticals said Glycopyrrolate tablets USP, 1 mg and 2 mg have an estimated market size of USD 15 million for 12 months ending December 2017.
The company now has a total of 81 ANDA approvals from the USFDA.
The stock was trading at Rs 617.60 apiece, up 0.32 per cent, on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app